

REGISTERED COMPANY NUMBER: 07476120 (England and Wales)
REGISTERED CHARITY NUMBER: 1142803

Trustees' Report and
Unaudited Financial Statements
for the Year Ended 31 December 2025
for
Global Sepsis Alliance

RAA Avalon Accounting Ltd
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Global Sepsis Alliance

Contents of the Financial Statements
for the Year Ended 31 December 2025

	Page
Trustees' Report	1 to 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10 to 11
Notes to the Financial Statements	12 to 17
Detailed Statement of Financial Activities	18 to 19

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2025

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Our charity's purposes as set out in the objects contained in the company's Memorandum of Association are for the public benefit to relieve sickness and promote and protect the physical and mental health of persons suffering from sepsis by:

- the provision of financial assistance, support, education, research, and practical advice; and
- increasing awareness and understanding of sepsis and its treatment amongst health professionals, corporations, governmental and non-governmental organizations, and the public.

The aims of our charity are to raise awareness and understanding of sepsis and its treatment and educate range of audiences, both professional and lay public. Our aims fully reflect the purposes that the charity was set up to further.

Ensuring Our Work Delivers Our Aims

The charity continues to be in its formative years, but we review our aims, objectives, and activities each year. This review outlines what we achieved and the outcomes of our work in the previous 12 months. The review also identifies where each key activity has been successful and the benefits they have brought to those groups of people we were established to help. The review also helps us ensure our aim, objectives, and activities remained focused on our stated purposes. We have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aim and objectives and in planning our future activities. In particular, the Trustees, Board, and Executive Committee jointly consider how planned activities will contribute to the aims and objectives they have set.

Review of Activities 2025

During 2025, the Global Sepsis Alliance (GSA) continued to strengthen its role as a global convener, advocate, and knowledge-sharing platform in the fight against sepsis. Through international partnerships, policy engagement, educational activities, and survivor involvement, GSA advanced its mission to reduce preventable sepsis deaths and disabilities worldwide.

The following activities represent the organization's most significant achievements during the year.

Global Advocacy and Policy Engagement

In February, GSA contributed to international policy discussions at the 156th Session of the World Health Organization (WHO) Executive Board in Geneva. GSA called on governments and global health stakeholders to prioritize sepsis within Universal Health Coverage packages and strengthen efforts to prevent, diagnose, and treat sepsis globally.

GSA also published a policy outlook entitled Investing in Sepsis Science for Future Pandemic Preparedness, highlighting the importance of sustained investment in sepsis research as a critical component of global health security.

In March, the European Sepsis Alliance (ESA), coordinated by GSA, held its 8th Annual Meeting at the European Parliament in Brussels, where a Call to Action was launched to encourage European policymakers to develop a coordinated response to sepsis across Europe.

In May, GSA convened the first-ever Official Side Event on Sepsis at the 78th World Health Assembly in Geneva in collaboration with multiple international partners, governments, and global health organizations. During the Assembly, GSA delivered official statements urging WHO Member States to recognize sepsis as a leading cause of preventable death and disability.

In September, GSA organized a side event during the 80th Session of the United Nations General Assembly in New York, further elevating sepsis on the global policy agenda.

Knowledge Sharing and Global Education

The 5th World Sepsis Congress, held in April, represented one of GSA's flagship activities. The free, fully virtual congress brought together almost 12,000 participants from more than 170 countries, with 68% of attendees joining from low- and middle-income countries.

The congress featured expert discussions on sepsis epidemiology, artificial intelligence, antimicrobial stewardship, integrated care pathways, innovations in diagnostics and treatment, and health systems strengthening. Importantly, it also amplified the voices of sepsis survivors and family members.

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2025

Throughout the year, GSA expanded its educational offerings through multiple webinars addressing key topics, including antimicrobial stewardship, sepsis management in resource-limited settings, and the intersection between antimicrobial resistance and sepsis.

Survivor and Community Engagement

In April, GSA established the Global Sepsis Survivor Committee (GSSC), creating a formal mechanism for survivors and family members to contribute to GSA's activities and strategic priorities.

Throughout the year, GSA continued to share personal stories from sepsis survivors and families around the world, helping to raise awareness and ensure that lived experiences remained central to advocacy efforts.

In November, GSA launched its Individual Membership Program, enabling survivors, healthcare professionals, researchers, advocates, and members of the public to directly support and participate in the organization's mission.

Strategic Partnerships and Global Collaboration

GSA strengthened existing partnerships and established new collaborations throughout 2025. In March, GSA announced a partnership with the International Fluid Academy to advance education and clinical collaboration in sepsis care.

The organization also continued developing the Global Sepsis Innovations Platform (GSIP), a multi-stakeholder initiative focused on accelerating innovation in sepsis prevention, diagnostics, treatment, and health system implementation.

In February, GSA hosted a symposium in Berlin entitled "Overcoming Silos by Synergizing the Fight Against Sepsis and Antimicrobial Resistance", bringing together experts from multiple disciplines to strengthen collaboration between the global sepsis and antimicrobial resistance communities.

Throughout the year, GSA actively participated in international health forums and maintained engagement with WHO, governments, parliamentarians, healthcare organizations, research institutions, and civil society partners to advance the objectives of the 2030 Global Agenda for Sepsis.

World Sepsis Day

World Sepsis Day in September remained one of GSA's most impactful awareness initiatives. Hundreds of events were organized worldwide by partners and supporters, helping to raise awareness of sepsis among healthcare professionals, policymakers, patients, and the general public.

GSA itself organized three international events, including a central press conference in Berlin and global policy events in Geneva and New York. The campaign also received high-level support from WHO Director-General Dr Tedros Adhanom Ghebreyesus, who delivered a video address to the global sepsis community.

Organizational Development

In June, GSA welcomed its newly elected Board for the 2025-2028 term. Throughout the year, the organization maintained regular engagement with its member organizations, Regional Sepsis Alliances, partners, and sponsors to strengthen governance, coordinate strategic priorities, and build momentum for future initiatives.

Collectively, these activities have further strengthened GSA's position as a leading global organization dedicated to reducing the burden of sepsis through advocacy, education, partnership building, survivor engagement, and policy development.

How Our Activities Deliver Public Benefit

The Global Sepsis Alliance exists to reduce the global burden of sepsis through advocacy, education, innovation, and international collaboration. Our activities deliver clear public benefit by raising awareness of sepsis among healthcare professionals, policymakers, and the general public; promoting early recognition and timely treatment; supporting survivors and families; and contributing to the development of global health policy. Through free access to high-quality educational resources such as the World Sepsis Congress, collaboration with the World Health Organization and national governments, and support for regional alliances, we help improve sepsis outcomes worldwide - particularly in low- and middle-income countries, where the burden is greatest.

Our work aligns with public health priorities, advances the Sustainable Development Goals, and ultimately saves lives by informing and empowering both professionals and communities to act on sepsis.

Sepsis, which is often misunderstood by the public as "blood-poisoning" is one of the leading causes of death around the world. Sepsis arises when the body's response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, and death, especially if not recognized early and treated promptly.

Global Sepsis Alliance

Trustees' Report for the Year Ended 31 December 2025

Between one third and one half of patients with sepsis die. In the developing world, sepsis accounts for 60-80% of lost lives per year in childhood, killing more than 6 million neonates and children yearly and is responsible for more than 100,000 cases of maternal sepsis. Every hour, over 1,000 people die from sepsis.

We have a simple message: sepsis must receive utmost priority as a medical emergency, so that all patients can expect to receive basic interventions, including antibiotics and intravenous fluids, within the first hour.

What Examples Exist of Who Has Benefited?

A wide range of individuals and communities have benefited from the work of the Global Sepsis Alliance. Healthcare professionals worldwide - particularly in low- and middle-income countries - have gained free access to the latest clinical knowledge and research through our educational events, such as the World Sepsis Congress and thematic symposia. Policymakers and public health authorities have drawn on our guidance and advocacy to develop or enhance national sepsis strategies, as seen with the SEPSIS Act in the United States and the launch of the 2030 Global Agenda for Sepsis. Sepsis survivors and their families have also benefited through platforms that amplify their voices, connect them with support networks, and raise public awareness. Additionally, organizations such as the Caribbean Sepsis and AMR Alliance have emerged with GSA support, enabling local responses to regional sepsis challenges. Collectively, these examples demonstrate how our work directly supports professionals, policymakers, and the public in reducing the harm caused by sepsis.

PLANS FOR FUTURE PERIODS

In 2026, the Global Sepsis Alliance (GSA) will continue to strengthen its position as a global leader in sepsis advocacy, education, and partnership building, with a particular focus on translating increased international awareness into sustained policy action and measurable health system improvements.

A key priority will be to further elevate sepsis on regional and global political agendas. GSA will continue its engagement with the World Health Organization, United Nations agencies, governments, and international partners to promote the integration of sepsis into broader health system strengthening, pandemic preparedness, and antimicrobial resistance strategies.

The European Sepsis Alliance will intensify its advocacy efforts at the European level, including engagement with the Irish Presidency of the Council of the European Union, with the aim of advancing coordinated action on sepsis across Europe.

GSA will continue to expand its educational activities through webinars, expert discussions, and freely accessible digital resources, ensuring that healthcare professionals, researchers, policymakers, and patient advocates worldwide have access to current evidence and best practices in sepsis prevention, diagnosis, and treatment.

A major priority for 2026 will be the organization and execution of the 6th World Sepsis Congress, to be held in April 2026 under the theme "Universal Sepsis Care for Newborns, Children, and Women". As GSA's flagship educational initiative, the free, fully virtual congress will bring together healthcare professionals, researchers, policymakers, patient advocates, survivors, and representatives from international organizations from around the world.

The congress will focus on improving equitable access to high-quality sepsis prevention, diagnosis, and treatment for some of the most vulnerable populations, while promoting multidisciplinary collaboration and the exchange of best practices. By ensuring unrestricted global access, GSA aims to strengthen knowledge sharing, support capacity building, and advance progress towards universal sepsis care worldwide.

The organization will further develop the Global Sepsis Innovations Platform (GSIP) to accelerate collaboration between researchers, clinicians, industry partners, innovators, and people with lived experience. Particular emphasis will be placed on supporting innovations in diagnostics, artificial intelligence, implementation science, and health system delivery.

Building on the successful establishment of the Global Sepsis Survivor Committee, GSA will strengthen survivor engagement and ensure that the perspectives of survivors and family members remain central to its advocacy and program development.

The Individual Membership Program, launched in 2025, will continue to be expanded to foster a broader global community of supporters and increase opportunities for participation in GSA activities.

World Sepsis Day will remain a flagship awareness initiative in 2026, with GSA supporting global campaigns and coordinating international events to increase public awareness and encourage policy action at national and international levels.

The organization will also continue to strengthen its network of member organizations, Regional Sepsis Alliances, and strategic partners, with the aim of fostering greater collaboration and accelerating progress towards reducing preventable sepsis deaths and disabilities worldwide.

Through these activities, GSA aims to further advance its vision of a world free of sepsis and contribute to achieving sustainable, equitable improvements in sepsis prevention, recognition, and care globally.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. The organization is a charitable company limited by guarantee, incorporated on December 22nd, 2010 and registered as a charity on June 8th, 2011. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In the event of the company being wound up members are required to contribute an amount not exceeding £1.00 GBP.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Recruitment and appointment of new trustees

The Directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as the Trustees. The day-to-day management of the company is the responsibility of the members of the Executive Committee who are elected to serve for a period of three years after which they must be re-elected at the next Annual General Meeting. All members of the Executive Committee give their time voluntarily and received no benefits from the charity.

Induction and training of new trustees

The Trustees are already familiar with the practical work of the charity. A formal induction and training program will be considered as and when new Trustees are appointed. This training will include:

- The obligations of Executive Board members.
- The main documents which set out the operational framework for the charity including the Memorandum and Articles.
- Resourcing and the current financial position as set out in the latest published accounts.
- Future plans and objectives.

Risk management

The Trustees have conducted a review of the major risks to which the charity is exposed. The charity is still in its formative years and therefore the risk assessment has been confined to an assessment of financial outlook and the ability of the charity to fund its current and future activities. The charity has three current employees and no property or significant investments. However, the need for the charity to conduct a more comprehensive risk assessment (for example to include the completion of a Risk Register and Health and Safety Review) will be conducted annually and a further determination made.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

07476120 (England and Wales)

Registered Charity number

1142803

Registered office

12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Trustees

Mr Philip Taylor Director
Dr. Konrad Anton Reinhart Director
Dr. Darren Ron Daniels Director

Company Secretary

Mr Philip Taylor

Global Sepsis Alliance

Trustees' Report
for the Year Ended 31 December 2025

REFERENCE AND ADMINISTRATIVE DETAILS

Independent Examiner

RAA Avalon Accounting Ltd
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Solicitors

Russell-Cooke LLP
2 Putney Hill
London
SW15 6AB

Bankers

Barclays Bank plc	Commerzbank
Aldermaston Road	Fischergasse 10
Tadley	07743
Basingstoke	Jena
Hampshire	Germany
RG26 4QA	

Executive Committee

Abdulelah Alhawsawi
Dennis Kredler
Imrana Malik
Maha Aljuaid
Ron Daniels
Shevin Jacob

Board Members

Abdulelah Alhawsawi, Alison Fox-Robichaud, Ally Hossain, Andrew Argent, Antonio Artigas, Ciaran Staunton, Dennis Kredler, Evangelos Giamarellos-Bourboulis, Halima Salisu Kabara, Imrana Malik, Maha Aljuaid, Mitchell Levy, Naoyuki Matsuda, Rafael Barberena Moraes, Ron Daniels, Sheila Myatra, Shevin Jacob, Steve McGloughlin, Tex Kissoon, Ulrika Knutsson.

Approved by order of the board of trustees on and signed on its behalf by:

.....
Mr Philip Taylor - Trustee

Independent Examiner's Report to the Trustees of
Global Sepsis Alliance

Independent examiner's report to the trustees of Global Sepsis Alliance ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Caroline Brazier

RAA Avalon Accounting Ltd
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Date:

Global Sepsis Alliance

Statement of Financial Activities
for the Year Ended 31 December 2025

		2025 Unrestricted fund £	2024 Total funds £
	Notes		
Income and endowments from			
Donations and legacies	2	308,583	67,357
Other trading activities	3	56,617	51,865
Total		<u>365,200</u>	<u>119,222</u>
 Expenditure on			
Raising funds	4	325,586	448,677
 NET INCOME/(EXPENDITURE)		 39,614	 (329,455)
 Reconciliation of funds			
Total funds brought forward		146,548	476,003
 Total funds carried forward		 <u>186,162</u>	 <u>146,548</u>

The notes form part of these financial statements

Global Sepsis Alliance

Balance Sheet
31 December 2025

		2025	2024
		Unrestricted	Total
		fund	funds
	Notes	£	£
Fixed assets			
Tangible assets	9	7,373	9,831
Current assets			
Debtors	10	157,458	127,569
Cash at bank		25,009	27,088
		182,467	154,657
Creditors			
Amounts falling due within one year	11	(3,678)	(17,940)
Net current assets		178,789	136,717
Total assets less current liabilities		186,162	146,548
NET ASSETS		186,162	146,548
Funds	12		
Unrestricted funds		186,162	146,548
Total funds		186,162	146,548

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

Global Sepsis Alliance

Balance Sheet - continued
31 December 2025

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on
and were signed on its behalf by:

.....
Mr Philip Taylor - Trustee

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

INCOME

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

TANGIBLE FIXED ASSETS

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance
Computer equipment	- 25% on reducing balance

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

2. DONATIONS AND LEGACIES

	2025	2024
	£	£
Donations	308,583	67,357

3. OTHER TRADING ACTIVITIES

	2025	2024
	£	£
Sponsorships	56,617	51,865

4. RAISING FUNDS

RAISING DONATIONS AND LEGACIES

	2025	2024
	£	£
Postage and stationery	1,423	3,498
Other direct cost	8,811	1,553
Travel subsistence & accommodation	18,363	11,339
Event costs	57,692	62,279
Support costs	239,297	370,008
	<u>325,586</u>	<u>448,677</u>

5. SUPPORT COSTS

	Management	Finance	Information technology
	£	£	£
Raising donations and legacies	221,121	825	5,833
	<u>221,121</u>	<u>825</u>	<u>5,833</u>
		Governance	
	Other	costs	Totals
	£	£	£
Raising donations and legacies	2,458	5,335	239,297
	<u>2,458</u>	<u>5,335</u>	<u>239,297</u>

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2025	2024
	£	£
Depreciation - owned assets	2,458	3,277

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2025 nor for the year ended 31 December 2024.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 December 2025 nor for the year ended 31 December 2024.

8. STAFF COSTS

	2025	2024
	£	£
Wages and salaries	150,906	238,053
	<u>150,906</u>	<u>238,053</u>

The average monthly number of employees during the year was as follows:

2025	2024
<u> </u>	<u> </u>

No employees received emoluments in excess of £60,000.

9. TANGIBLE FIXED ASSETS

	Plant and machinery	Fixtures and fittings	Computer equipment	Totals
	£	£	£	£
COST				
At 1 January 2025 and 31 December 2025	<u>1,710</u>	<u>8,172</u>	<u>25,238</u>	<u>35,120</u>
DEPRECIATION				
At 1 January 2025	879	6,872	17,538	25,289
Charge for year	<u>208</u>	<u>325</u>	<u>1,925</u>	<u>2,458</u>
At 31 December 2025	<u>1,087</u>	<u>7,197</u>	<u>19,463</u>	<u>27,747</u>
NET BOOK VALUE				
At 31 December 2025	<u>623</u>	<u>975</u>	<u>5,775</u>	<u>7,373</u>
At 31 December 2024	<u>831</u>	<u>1,300</u>	<u>7,700</u>	<u>9,831</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Trade debtors	137,894	108,037
Investment	18,639	18,639
VAT	925	893
	<u>157,458</u>	<u>127,569</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Social security and other taxes	1,574	3,832
Other creditors	94	-
Net wages	-	12,248
Accrued expenses	2,010	1,860
	<u>3,678</u>	<u>17,940</u>

12. MOVEMENT IN FUNDS

	At 1.1.25	Net movement in funds	At 31.12.25
	£	£	£
Unrestricted funds			
General fund	146,548	39,614	186,162
	<u>146,548</u>	<u>39,614</u>	<u>186,162</u>
TOTAL FUNDS	<u>146,548</u>	<u>39,614</u>	<u>186,162</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	365,200	(325,586)	39,614
	<u>365,200</u>	<u>(325,586)</u>	<u>39,614</u>
TOTAL FUNDS	<u>365,200</u>	<u>(325,586)</u>	<u>39,614</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

12. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.24 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	476,003	(329,455)	146,548
TOTAL FUNDS	476,003	(329,455)	146,548

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	119,222	(448,677)	(329,455)
TOTAL FUNDS	119,222	(448,677)	(329,455)

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.24 £	Net movement in funds £	At 31.12.25 £
Unrestricted funds			
General fund	476,003	(289,841)	186,162
TOTAL FUNDS	476,003	(289,841)	186,162

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	484,422	(774,263)	(289,841)
TOTAL FUNDS	484,422	(774,263)	(289,841)

Global Sepsis Alliance

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

13. RELATED PARTY DISCLOSURES

Insights in Healthcare Ltd provided secretariat services to Global Sepsis Alliance during the year totalling £3,325 (PY - £3,600). Mr. Philip Taylor is common director in both company.

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2025

	2025 £	2024 £
Income and endowments		
Donations and legacies		
Donations	308,583	67,357
Other trading activities		
Sponsorships	56,617	51,865
Total incoming resources	365,200	119,222
Expenditure		
Raising donations and legacies		
Postage and stationery	1,423	3,498
Other direct cost	8,811	1,553
Travel subsistence & accommodation	18,363	11,339
Event costs	57,692	62,279
	86,289	78,669
Support costs		
Management		
Wages	150,906	238,053
Computer Cost	3,670	6,155
Insurance	34,757	49,719
Office Rent	17,144	15,789
Staff welfare	-	240
Telephone	861	813
Advertising	1,656	-
Office cost	-	719
Bookkeeping	1,224	1,035
Consultancy	7,393	35,501
Foreign Exchange Loss	3,510	4,892
	221,121	352,916
Finance		
Light and heat	275	120
Sundry Expense	34	-
Bank charges	364	286
Paypal charges	152	102
	825	508

This page does not form part of the statutory financial statements

Global Sepsis Alliance

Detailed Statement of Financial Activities
for the Year Ended 31 December 2025

	2025	2024
	£	£
Finance		
Information technology		
Website development	5,833	5,866
Other		
Plant and machinery	208	277
Fixtures and fittings	325	433
Computer equipment	1,925	2,567
	2,458	3,277
Other 2		
Subscription	3,725	1,981
Governance costs		
Accountancy fees	2,010	1,860
Secretary	3,325	3,600
	5,335	5,460
Total resources expended	325,586	448,677
Net income/(expenditure)	<u>39,614</u>	<u>(329,455)</u>

This page does not form part of the statutory financial statements